Ikena Oncology(IKNA) - 2025 Q3 - Quarterly Results

Exhibit 99.1 ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team $142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007's unique molecular attributes; strong patient enrollment continues ...